Increasing Medical Marijuana and Cannabidiol Research
Headline: Orders Faster Research and Rescheduling for Medical Marijuana and Cannabidiol
What it does: Agencies must complete marijuana rescheduling rulemaking, work with Congress on hemp product law updates, and develop real-world research to improve access and guide care.
- Speeds completion of rulemaking to move marijuana to Schedule III.
- Calls for updates to hemp product definitions and THC limits.
- Requires health agencies to create real-world research to guide standards of care.
Summary
This order directs the Attorney General to finish the rulemaking to reschedule marijuana to Schedule III, asks a White House legislative official to work with Congress to update laws on hemp-derived cannabinoid products, and requires health agencies to develop real-world research methods to improve access and inform standards of care.
It affects patients who use medical marijuana or CBD, healthcare providers, researchers, and product makers by aiming to expand research, set guidance on THC limits, and give doctors better information about risks and benefits, especially for vulnerable groups like adolescents and seniors.
Ask about this order
Ask questions about this executive order and its implications.
What agencies are affected by this order?
How does this order change existing policy?
What are the practical implications of this order?